Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endothelial monocyte activating polypeptide II
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intraperitoneal
01
Overview
Endothelial monocyte activating polypeptide II (EMAP) is a polypeptide that acts as an antiangiogenic agent. It has been investigated for its ability to enhance the effects of gemcitabine in experimental pancreatic ductal adenocarcinoma (PDAC) and has shown antitumor activity in combination with gemcitabine and sorafenib in preclinical models.
- Other names
- EMAP
02
Targets
CCR3 (C-C chemokine receptor type 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Endothelial monocyte activating polypeptide II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endothelial monocyte activating polypeptide II.